Akebia Therapeutics (AKBA) Net Cash Flow (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Net Cash Flow data on file, last reported at -$22.2 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 136.08% year-over-year to -$22.2 million in Q1 2026; TTM through Mar 2026 was $49.3 million, a 31.0% decrease from a year earlier, with the FY2025 full-year figure at $133.0 million, up 1382.48% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$22.2 million, down from $18.4 million in the prior quarter.
• Over the last five years, Net Cash Flow for AKBA reached as high as $61.5 million in Q1 2025 and fell as low as -$54.7 million in Q4 2022.
• Historically, Net Cash Flow has averaged $735823.5 across 5 years, with a median of -$2.5 million in 2024.
• Across the five-year window, Net Cash Flow sank 919.93% in 2023 and surged 6527.27% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$54.7 million in 2022, then jumped by 93.42% to -$3.6 million in 2023, then soared by 596.3% to $17.9 million in 2024, then gained by 3.06% to $18.4 million in 2025, then slumped by 220.6% to -$22.2 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$22.2 million in Q1 2026, $18.4 million in Q4 2025, and $29.1 million in Q3 2025.